Glp 1 Comprehensive Panel
A GLP-1 comprehensive lab panel that checks glucose control, insulin patterns, lipids, liver and kidney markers to guide safer therapy and progress tracking.
This panel bundles multiple biomarker tests in one order—your report explains how results fit together.
When you are using a GLP-1 medication (or considering one), a single lab value rarely tells the whole story. This comprehensive lab panel bundles multiple blood tests into one draw so you can see how glucose control, insulin dynamics, cholesterol, and organ safety markers are moving together over time.
Do I need this panel?
This panel can be a good fit if you are starting, changing, or maintaining a GLP-1 plan and you want a broader view than “just an A1c.” Many people notice that their day-to-day glucose readings, weight changes, appetite, and energy do not always match what A1c alone suggests, especially early in therapy or during rapid weight loss.
You may also benefit from this panel if you are tracking cardiometabolic risk alongside weight loss. GLP-1 therapy can improve triglycerides and other lipid markers for many people, but the direction and timing vary. Seeing glucose, insulin, and lipids together helps you and your clinician decide whether your plan is working as intended—or whether something else (sleep, stress, diet composition, medication timing, or another condition) is affecting your results.
This panel is also useful if you have concerns about medication monitoring, such as nausea limiting protein intake, a weight-loss plateau, or worries about losing muscle. While labs cannot directly measure muscle loss, they can reveal patterns that often travel with under-fueling, dehydration, or inadequate protein and micronutrient intake (for example, changes in kidney markers, liver enzymes, or fasting glucose).
Your results are meant to support clinician-directed care and shared decision-making. They are not a diagnosis on their own, and the best interpretation comes from combining your lab pattern with symptoms, medications, and your medical history.
This panel includes standard clinical chemistry and immunoassay measurements; reference ranges and units can vary by lab, so interpretation should focus on patterns and trends over time.
Lab testing
Order the Glp 1 Comprehensive Panel
Schedule online, results typically within about a week
Clear reporting and optional clinician context
HSA/FSA eligible where applicable
Get this panel with Vitals Vault
Vitals Vault makes it straightforward to order a GLP-1-focused lab panel and get results you can actually use. You can test to establish a baseline before therapy, check early response after a dose change, or monitor longer-term progress and safety markers as your weight and glucose control shift.
After your results are in, you can use PocketMD to put the numbers into context—especially when multiple markers move in different directions (for example, A1c improving while fasting glucose is still elevated, or triglycerides dropping while LDL-C rises). PocketMD can help you generate questions to bring to your prescribing clinician and decide what to retest and when.
If you are optimizing therapy, trends matter. Repeating the same panel at consistent intervals (and under similar conditions, such as fasting status and time of day) makes it easier to see whether changes are due to your plan or due to short-term variability.
- One blood draw that bundles glucose, insulin, lipids, and safety markers
- Trend-friendly results for before/after comparisons
- PocketMD support for pattern-based interpretation and next-step questions
- Designed for GLP-1 users and cardiometabolic risk tracking
Key benefits of Glp 1 Comprehensive Panel testing
- Shows glucose control from multiple angles (short-term glucose and longer-term A1c) instead of relying on one number.
- Adds insulin context so you can spot insulin resistance patterns even when glucose looks “okay.”
- Pairs glycemic markers with a lipid profile to track cardiometabolic risk while you lose weight.
- Includes liver markers that can shift with fatty liver improvement, rapid weight loss, or medication effects.
- Includes kidney and electrolyte markers that can reflect hydration status and overall safety during appetite changes.
- Helps explain common “mismatch” scenarios, like improving A1c with persistent fasting glucose elevation or vice versa.
- Supports smarter retesting after dose changes by giving a repeatable baseline across multiple systems.
What is the Glp 1 Comprehensive Panel?
The Glp 1 Comprehensive Panel is a bundled lab panel—meaning it measures multiple blood biomarkers in one order—to help you monitor metabolic health while using (or preparing to use) GLP-1–based therapy. GLP-1 medications can affect appetite, gastric emptying, body weight, glucose regulation, and downstream cardiometabolic risk factors. Because those changes do not always move in lockstep, a multi-marker panel is often more informative than ordering a single test.
Rather than focusing on one analyte, this panel is designed to answer a few practical questions: Are your average glucose levels improving? Are fasting glucose and insulin patterns consistent with better insulin sensitivity? Are your cholesterol and triglycerides moving in a favorable direction? Are liver and kidney markers stable as your diet and weight change?
You can use this panel before starting therapy to establish a baseline, after a dose change to assess early response, or periodically to monitor progress and safety. The most useful interpretation comes from comparing your results to prior results and to your real-world data (weight trend, appetite, side effects, activity, and any home glucose readings).
Why a panel matters on GLP-1 therapy
GLP-1 therapy can lower A1c, reduce post-meal glucose spikes, and improve triglycerides for many people, but individual responses vary. Some people see fasting glucose improve later than A1c, and some see LDL-related markers rise during rapid weight loss even as triglycerides fall. A panel helps you see these patterns early so you can discuss adjustments with your clinician.
What this panel is not
This panel does not measure GLP-1 drug levels, does not diagnose diabetes complications by itself, and does not replace clinical evaluation for symptoms like severe abdominal pain, persistent vomiting, or signs of dehydration. It is a monitoring tool that becomes more powerful when repeated and interpreted in context.
What do my panel results mean?
Low (or lower-than-expected) patterns across the panel
In a GLP-1 monitoring context, “low” often shows up as lower A1c and lower fasting glucose compared with your baseline, which is usually a positive response. However, some low patterns can be a signal to check your overall intake and hydration—such as low-normal sodium, low bicarbonate (CO2), or rising BUN/creatinine ratio alongside reduced fluid intake. If glucose markers are very low or you have symptoms of hypoglycemia (shakiness, sweating, confusion), your clinician may reassess other glucose-lowering medications, meal timing, and your overall plan.
Optimal patterns across the panel
An optimal panel pattern typically looks like improving or stable A1c with fasting glucose moving toward your target range, fasting insulin that is not elevated for your glucose level, and a lipid profile trending in a favorable direction (often lower triglycerides and improved non-HDL cholesterol). Liver enzymes are usually stable or improving, and kidney markers remain steady without signs of dehydration. The key is consistency: when multiple categories improve together and stay stable across repeat tests, it is a strong sign your therapy and lifestyle plan are aligned.
High (or higher-risk) patterns across the panel
Higher-risk patterns can include persistently elevated A1c and fasting glucose, fasting insulin that remains high (suggesting ongoing insulin resistance), or a widening gap where A1c improves but fasting glucose stays elevated—sometimes pointing to dawn phenomenon, sleep/stress effects, or medication timing issues. On the lipid side, triglycerides that remain high can track with insulin resistance and excess carbohydrate intake, while LDL-C or ApoB-related risk may rise during rapid weight loss in some people. High liver enzymes can reflect fatty liver, alcohol, medication effects, or other liver conditions and should be interpreted with your clinician, especially if values are rising over time.
Factors that influence your panel results
Your pattern can shift based on fasting status, recent exercise, alcohol intake, hydration, and short-term calorie restriction—common variables when appetite changes on GLP-1 therapy. Medications matter too: insulin, sulfonylureas, steroids, thyroid medication, statins, and some psychiatric medications can change glucose and lipid markers. Rapid weight loss can temporarily change cholesterol transport and liver enzymes, and dehydration from nausea or reduced intake can concentrate kidney markers. For the cleanest trend, try to test under similar conditions each time (same fasting window, similar time of day, and stable medication routine unless your clinician advises otherwise).
What’s included in this panel
- % Saturation
- Absolute Band Neutrophils
- Absolute Basophils
- Absolute Blasts
- Absolute Eosinophils
- Absolute Lymphocytes
- Absolute Metamyelocytes
- Absolute Monocytes
- Absolute Myelocytes
- Absolute Neutrophils
- Absolute Nucleated Rbc
- Absolute Plasma Cells
- Absolute Prolymphocytes
- Absolute Promyelocytes
- Absolute Reactive Lymphocytes
- Adiponectin
- Albumin
- Albumin, Urine
- Albumin/Creatinine Ratio, Random Urine
- Albumin/Globulin Ratio
- Alkaline Phosphatase
- Alt
- Amorphous Sediment
- Amylase
- Apolipoprotein B
- Appearance
- Ast
- Bacteria
- Band Neutrophils
- Basophils
- Bilirubin
- Bilirubin, Total
- Blasts
- Bun/Creatinine Ratio
- Calcium
- Calcium Oxalate Crystals
- Carbon Dioxide
- Casts
- Chloride
- Chol/Hdlc Ratio
- Cholesterol, Total
- Color
- Copper
- Creatinine
- Creatinine, Random Urine
- Crystals
- Dhea Sulfate
- Egfr
- Eosinophils
- Estradiol
- Ferritin
- Folate, Serum
- Globulin
- Glucose
- Granular Cast
- Hdl Cholesterol
- Hdl Large
- Hematocrit
- Hemoglobin
- Hemoglobin A1C
- Homocysteine
- Hs Crp
- Hyaline Cast
- Insulin
- Iodine, Serum/Plasma
- Iron Binding Capacity
- Iron, Total
- Ketones
- Ldl Medium
- Ldl Particle Number
- Ldl Pattern
- Ldl Peak Size
- Ldl Small
- Ldl-Cholesterol
- Ldl/Hdl Ratio
- Leptin
- Leukocyte Esterase
- Lipase
- Lymphocytes
- Magnesium
- Mch
- Mchc
- Mcv
- Metamyelocytes
- Monocytes
- Mpv
- Myelocytes
- Neutrophils
- Nitrite
- Non Hdl Cholesterol
- Nucleated Rbc
- Occult Blood
- Ph
- Phosphate (As Phosphorus)
- Plasma Cells
- Platelet Count
- Potassium
- Prealbumin
- Progesterone
- Prolymphocytes
- Promyelocytes
- Protein
- Protein, Total
- Rbc
- Rdw
- Reactive Lymphocytes
- Red Blood Cell Count
- Renal Epithelial Cells
- Sex Hormone Binding Globulin
- Sodium
- Specific Gravity
- Squamous Epithelial Cells
- T3, Free
- T4, Free
- Testosterone, Free
- Testosterone, Total, Ms
- Transferrin
- Transitional Epithelial Cells
- Triglycerides
- Triple Phosphate Crystals
- Tsh
- Urea Nitrogen (Bun)
- Uric Acid Crystals
- Vitamin B12
- Vitamin D, 25-Oh, D2
- Vitamin D, 25-Oh, D3
- Vitamin D, 25-Oh, Total
- Wbc
- White Blood Cell Count
- Yeast
- Zinc
Frequently Asked Questions
Do I need to fast for this panel?
Fasting is usually recommended because the panel includes fasting glucose, fasting insulin, and lipid markers that are easier to compare over time when you test under similar conditions. If you cannot fast, you can still test, but tell your clinician (and note it for yourself) so you do not over-interpret triglycerides, glucose, or insulin changes driven by a recent meal.
How often should you repeat a GLP-1 monitoring panel?
Many people retest after a meaningful change—such as starting therapy, changing dose, or making a major nutrition/training shift—and then at regular intervals to track trends. The right cadence depends on your baseline A1c, medications, symptoms, and goals. Your clinician can help you choose timing that matches how quickly your markers are expected to change.
Why can A1c improve while fasting glucose is still high?
A1c reflects an average over roughly the past 2–3 months, while fasting glucose is a single point in time. On GLP-1 therapy, post-meal glucose can improve early, pulling A1c down, while fasting glucose lags due to dawn phenomenon, sleep disruption, stress hormones, or medication timing. Looking at fasting insulin and other markers alongside A1c helps you interpret the pattern.
Can GLP-1 medications affect cholesterol results?
They can. Many people see triglycerides improve as insulin resistance improves and weight decreases. LDL-C (and related risk markers) may improve, stay the same, or sometimes rise during rapid weight loss because cholesterol trafficking changes as fat stores shrink. The most useful approach is to look at the full lipid pattern and trend it over time rather than reacting to a single result.
Is this panel the same as ordering A1c alone?
No. A1c alone gives you one long-term glucose metric. This panel bundles multiple categories—glucose and insulin dynamics, lipids, and organ function markers—so you can interpret your progress and safety in a more complete way, especially during dose changes or rapid weight loss.
What should I do if my kidney or electrolyte markers look off?
Do not ignore it, especially if you have nausea, vomiting, diarrhea, dizziness, or reduced fluid intake. Mild shifts can happen with dehydration, but rising creatinine, lower eGFR, or significant electrolyte abnormalities should be reviewed promptly with your clinician. If you feel unwell or cannot keep fluids down, seek urgent care.
What’s the difference between this panel and an insulin-and-glucose-focused panel?
An insulin-and-glucose-focused panel is narrower and centers on glucose, insulin, and related calculations. This comprehensive panel adds broader cardiometabolic and safety context—especially lipids and organ function markers—so you can see how multiple systems are responding together.